• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.
Programs

Principal Investigator(s)

Oliver Karam

Coordinator(s)

 To come.

Status

Enrolling

Plasma Transfusions in Critically Ill Children - Point Prevalence Study

Background: Although plasma transfusions are frequently prescribed for critically ill patients, most clinical uses of plasma are not supported by evidence. Plasma transfusions do not seem to correct mild coagulation abnormalities based on INR testing, but seem to be independently associated with worse clinical outcome, in moderately bleeding patients.

Objectives: To identify patient characteristics and clinical conditions leading to plasma transfusions in critically ill children and to assess the effect of plasma transfusions on coagulation tests.

Study design: Point-prevalence study, i.e. international multicenter cross-sectional observational study in PICUs, involving 22 countries. On 6 pre-defined weeks over a six-month period, data regarding clinical conditions having led to plasma transfusions will be collected.  All patients having received at least one plasma transfusion on the selected study days will be included. The primary endpoint will be the identification of clinical conditions associated with the first plasma.

Expected results and future studies: We expect to show that a third of plasma is transfused to critically ill children who are not bleeding and not going to need invasive procedures. As these are the patients who will probably benefit the least from plasma transfusions, we will then design a randomized controlled trial on plasma transfusion strategies, targeting the population identified by this point-prevalence study.

Conclusion: This first international point-prevalence study will allow us to better characterize which critically ill children receive plasma transfusions. We will then be able to address this issue in a randomized controlled trial on plasma transfusion strategies.

Co-Investigators

To come.

Participating Centers

To come.